drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous adoptive T‑cell therapy)
drug_description
An autologous, ex vivo–expanded T‑cell therapy composed of cytotoxic T lymphocytes engineered/selected to recognize personalized tumor‑specific antigens (neoantigens) via native TCRs; administered intraventricularly to target pediatric embryonal brain tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous, ex vivo–expanded cytotoxic T cells selected for reactivity to patient-specific tumor antigens/neoantigens via native TCRs. After intraventricular administration, TCR recognition of peptide–MHC on tumor cells activates CTLs to kill targets through perforin/granzyme release and cytokine-mediated immune responses in the CNS.
drug_name
Multi–tumor antigen–specific cytotoxic T lymphocytes (TSA‑T)
nct_id_drug_ref
NCT06193759